Healingovation, a Beijing-based innovator in surgical robots and intelligent diagnostic and therapeutic equipment, has reportedly secured more than RMB 60 million (USD 8.3 million) in a pre-Series A++ financing round. The round was led by CD Capital, with participation from Legend STAR, and returning investors Shunwei Capital, Lilly Asia Ventures, and Zhonghai Investment. The funds will be directed towards the clinical study of its MetaFlow high-energy water jet autonomous surgical robot, also known as an aquablation surgical robot, and the research and development of new product pipelines.
Established in 2021, Healingovation specializes in products for urological surgery, interventional surgery, and transluminal surgery. The company’s aforementioned product is currently in the regulatory study phase for prostate hyperplasia surgery.- Flcube.com
